Interleukin-6 (IL-6) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments

Overview

IL-6 is transcribed by IL-6 gene that encodes a cytokine, which functions in inflammation and maturation of B cells. The IL-6 protein can induce fever in patients suffering from autoimmune diseases, thereby acting as endogenous pyrogens. The protein is mainly produced at the sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through IL-6α receptor. IL-6 gene plays a significant role in wide variety of inflammation-associated disorders, including systemic juvenile rheumatoid arthritis. The role of IL-6 protein has been seen in various diseases such as cancer, schizophrenia, diabetes mellitus, systemic juvenile rheumatoid arthritis, asthma, and depression. The IL-6 inhibitors target the IL-6 receptors (IL-6Rs), thereby preventing the binding of IL-6 ligands to IL-6 receptors. Thus, inhibiting the entire IL-6 signal transduction.

Actmera (F. Hoffmann-La Roche Ltd.), Kevzara (Regeneron Pharmaceuticals Inc. and Sanofi-aventis Groupe), and Sylvant (Janssen Global Services LLC) are amongst the U.S. Food and Drug Administration (USFDA) approved medications targeting IL-6 signaling pathway and antagonizing its mechanism of action.

Positive clinical trial results and strategic decisions of companies to collaborate with other companies are also facilitating drug development in IL-6 inhibitors pipeline arena. Additionally, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the National Institutes of Health (NIH).

Pipeline Analysis

As of March 2019, the IL-6 inhibitors pipeline comprised 25+ drugs in different stages of development.

Competitive Landscape

Some of the companies involved in the development of IL-6 inhibitors include F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Sanofi-aventis Groupe, Janssen Global Services LLC, Novimmune SA, and UCB Pharma.

Report Insights

Some highlights of the report “Interleukin-6 (IL-6) Inhibitors ­– Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments”, have been mentioned below:

• Detailed pipeline analysis of therapeutics candidates that are being developed as IL-6 inhibitors, and estimates and analyses of emerging therapies and their progress status in different phases of development
• Comprehensive insights into pipeline products, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences
• Competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with relevance to IL-6 inhibitors
• Analysis of marketed IL-6 inhibitors
• Detailed regulatory framework for drug approval in the U.S., Europe, and Japan
• Key winning strategies of the companies involved in the development of IL-6 inhibitors, followed by Pharma Proff’s views